Ardelyx (ARDX) has quietly established itself as one of the most fascinating biotech stories, trading at under $10. With two ...
Independent DSMB reports zero device-related safety issuesSupports potential clinical benefitTrial sample size re-estimated to strengthen ...
IMDX to host symposium on Wednesday, September 24th to discuss GraftAssureIQ™ at International Association of Therapeutic Drug Monitoring and ...
The show — one of Warren’s longest sets ever at 18 songs and a solid hour and a half — ran through most of his newest album ...
Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily ...
Once-daily oral GLP-1 drug orforglipron leads to significant, dose-dependent weight loss and metabolic benefits without diabetes.
The former Tornado football star, and the school’s football, baseball, and weightlifting coach, was a father figure to many ...
PALSONIFY™ (paltusotine) INDICATION: PALSONIFY is a somatostatin receptor agonist indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom ...
FG-3246 Phase 2 dose optimization trial to enroll 75 patients with metastatic castration-resistant prostate cancer (mCRPC) in the post-androgen receptor signaling inhibitor (ASRI) and pre-chemotherapy ...
Xencor remains a 'Strong Buy' in my view despite the stock's 60% performance decline. Click here to find out why XNCR stock ...
Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.
Doctors are experimenting with using lower doses of blockbuster cancer drugs. It could help hundreds of thousands of lives — if pharmaceutical companies would allow it.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback